secwatch.observer — SEC 8-K summary
======================================

Issuer:     89bio, Inc. (—)
CIK:        0001785173
Form:       8-K
Filed at:   2025-10-30T23:59:59+00:00
Accession:  0001193125-25-257616
Event type: m_and_a
Sentiment:  neutral
Materiality: 1.00
Item codes: 1.02, 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Roche completes acquisition of 89bio for $14.50/share + CVR; stock to be delisted
--------------------------------------------------------------------------------

- Total cash consideration $14.50 per share plus one CVR worth up to $6.00 per share.
- 94.1M shares validly tendered (60.49%) plus 42.5M shares via guaranteed delivery (27.31%).
- Merger closed October 30; company becomes wholly owned by Roche; Nasdaq delisting requested.
- Loan agreement with K2 HealthVentures terminated and fully paid at closing.
- Board and officers replaced; transaction bonuses for three executives: $75k, $250k, $300k.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1785173/000119312525257616/0001193125-25-257616-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1785173/000119312525257616/d48446d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-257616

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer